• Opus Genetics secured FDA clearance for Ryzumvi, phentolamine ophthalmic solution 0.75%, to treat presbyopia in adults, expanding its U.S. indications.
• Already reported Phase 3 VEGA-2 and VEGA-3 results met all primary and key secondary efficacy goals, with no treatment-related serious adverse events.
• The presbyopia approval triggers a milestone payment under a global licensing agreement with Viatris, which holds exclusive U.S. commercialization rights.
• Ryzumvi is already marketed in the U.S. to treat pharmacologically induced pupil dilation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610161200PRIMZONEFULLFEED9847461) on October 16, 2026, and is solely responsible for the information contained therein.